SOURCE: NI Research

December 03, 2007 09:00 ET

NI Research Releases Publications on Spinal Cord Injury and Alzheimer's

CARDIFF, CA--(Marketwire - December 3, 2007) - NI Research today announced the release of two publications:

1) The December issue of NeuroInvestment reviews and evaluates therapeutics-under-development for the treatment of spinal cord injury. SCI is a multi-faceted disorder which will eventually require therapies which protect remaining cells, foster regeneration, and allow regrowth to cross gaps and barriers of scar tissue. While neurorehabilitative and neurosurgical techniques have become more effective, and interventions like hypothermia have had some positive results, there is still a pronounced lack of proactive interventions available. Even though the absolute number of new patients is relatively small, the consequences of spinal cord injury are so dire, in terms of lifelong disability, that this does constitute a major, billion-dollar plus market opportunity. Among the programs reviewed are those from Biogen-Idec, Geron, NeuralStem, Novartis, Proneuron, Sangamo, Sygnis, Neuraxo, and the promising Cethrin program being developed by Alseres (NASDAQ: ALSE). The December issue also has pointed commentary regarding Neurochem and Shire, and a Focus Review of Memory Pharmaceuticals.

2) NI Research is pleased to announce the release of Alzheimer's 2008, our special report on the state of the race to develop therapeutics for the treatment of Alzheimer's. This publication provides an overview of the pathophysiological models and therapeutic avenues being pursued, while discussing program prospects with a degree of specificity and frankness not to be found in other publications in this area. Alzheimer's 2008 also includes a database of Alzheimer's development programs, and discusses the best Alzheimer's partnering candidates. Alzheimer's 2008 builds upon the Alzheimer's coverage provided by NeuroInvestment, revised and updated so that it is current at the time of release. Programs reviewed include those from Elan, Acumen, Medivation, Targacept (NASDAQ: TRGT), AstraZeneca, Allon Therapeutics (TSX: NPC), Intellect Neuroscience, Kinexis, Pfizer, American Life Sciences Pharmaceuticals, Prana Biotechnology, Cortex (AMEX: COR), Roche, Novartis, and many more. Alzheimer's 2008 has been designed to be the most concise and forthright overview of Alzheimer's therapeutics-in-development available today. It has also been priced at a level that makes it affordable for companies and institutions of all sizes.

27 pages   2 Tables   US$595

(Subscribers to NeuroInvestment can purchase Alzheimer's 2008 for $395)

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year subscription is $1500 ($1600 as of January 1), email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery outside North America. A three month trial subscription is US$600.

For more information and order forms, go to:

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and has added CNS 2007-8, an annual compendium of all neuro-oriented R&D programs organized by disorder, and Alzheimer's 2008. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies.

Contact Information